DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, is making noteworthy strides in its mission to develop innovative therapies for conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke. Recent developments at the company have positioned it in the spotlight, especially as it gears up to participate in the Cantor Global Healthcare Conference in New York City from September 3-5, 2025. The conference will feature a fireside chat with Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, providing a platform for the company to engage with investors and discuss its pipeline and future directions.The participation at the conferen...
Strategic Advancements and Scientific Progress at DiaMedica Therapeutics: A Look at Recent Developments MINNEAPOLIS DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company at the forefront of innovating therapies for critical conditions like preeclampsia, fetal growth restriction, and acute ischemic stroke, has been making waves in the healthcare industry with a series of significant developments.In a robust move to bolster its financial and strategic footing, DiaMedica recently concluded a substantial $30.1 million private placement of common shares to accredited investors. This initiative, which involved the sale of approximately 8.6 million common shares at a price of $3...
CSIMarket.com In an ever-evolving landscape of biopharmaceutical innovation, DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stands at a crucial juncture as it prepares to participate in key investor conferences in May 2025, while simultaneously advancing its clinical trials for promising therapeutics aimed at severe ischemic diseases and preeclampsia. Upcoming Investor Conferences: A Platform for Engagement and Growth DiaMedica is set to showcase its potential at the 2025 RBC Capital Markets Global Healthcare Conference , taking place from May 20th to May 21st, 2025 , in New York City. This conference presents a vital opportunity for the company to engage with investors and stakeholders through one-on-o...
In an exciting development for maternal health, DiaMedica Therapeutics Inc. (Nasdaq: DMAC), the Minneapolis-based biopharmaceutical company renowned for its commitment to advancing treatments for severe ischemic diseases, has announced the dosing of its first patient in a Phase 2 clinical trial examining the efficacy of DM199 in the treatment of preeclampsia (PE). This novel investigational therapy holds promise not only for understanding the complex biology underlying preeclampsia but also for offering new avenues for intervention in this serious condition.Preeclampsia, a disorder that affects approximately 5-8% of pregnancies, is characterized by the onset of hypertension and proteinuria after the 20th wee...
DiaMedica Therapeutics Inc. a biopharmaceutical company based in Minneapolis and listed on the Nasdaq under the ticker DMAC, is poised to release its financial results for the third quarter of 2024. The financial report will be made available after the market closes on Wednesday, November 13, 2024. This announcement comes as the company continues its commitment to developing innovative treatments for severe ischemic diseases, which encompass conditions resulting from restricted blood flow.Following the release of its financial results, DiaMedica will hold a live conference call on Thursday, November 14, 2024, at 7:00 AM Central Time. This call will provide an essential platform for the company to detail its ...
DiaMedica Therapeutics to Participate in September Conferences Amidst Financial Challenges DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has recently announced its participation in key investor conferences slated for September. The company, which focuses on developing its recombinant KLK1 (DM199) for treatments in acute ischemic stroke and preeclampsia, will present at the HC Wainwright Global Investment Conference in New York. Despite significant advancements in its clinical trials, DiaMedica is facing notable financial challenges, evidenced by its recent net loss and return on assets performance. Upcoming Conference Participation DiaMedica Therapeutics has conf...
DiaMedica Therapeutics Announces $11.8 Million Private Placement with Accredited Investors Minneapolis DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company dedicated to developing novel treatments for severe ischemic diseases, revealed today that it has secured definitive agreements for the private placement of its common shares. This action is set to generate gross proceeds of approximately $11.8 million.The private placement involved agreements with accredited investors, further emphasizing the company s targeted strategy to shore up its financial resources without diluting the stock in the public market. Notably, a placement agent was not employed in this transaction,...
Sources:
Diamedica Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Diamedica Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Diamedica Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
